Search results

Lyphe is proud to introduce the Noidecs V Range, a new line of medical cannabis products that simplifies treatment options for patients while addressing the biggest challenges in the UK market, affordability, accessibility, and supply chain resilience. This new product line focuses on...

Germany has taken a groundbreaking step in cannabis reform with the launch of its medical cannabis pilot programme under the Cannabis Control Act (CanG). This initiative, which integrates research, regulation, and innovation, is designed to guide the nation’s cannabis policies while setting a...

Kamala Harris’ endorsement of cannabis legalisation, made during an appearance on All The Smoke, represents a pivotal shift in her campaign and positions her as one of the key figures advocating for cannabis reform in the United States. While Harris has supported decriminalisation in the past...

Recent research by Lindsey Metcalf McGrath and Helen Beckett Wilson shines a light on the lived experiences of UK cannabis patients, revealing a stark disconnect between legal prescriptions and the social realities of cannabis use. While prescribing cannabis has been legal in the UK since 2018...

Welcome to August’s analysis of the MedBud traffic data. The most interesting month we have had yet, and a clear sign that the data we analyse provides a real time accurate representation of how the sector is performing. In terms of the MedBud site it currently averages over a million monthly...

As the use of prescription cannabis becomes increasingly common in the UK, landlords and housing associations are facing a new legal challenge: how to accommodate tenants who use medical cannabis. Despite cannabis being legal for medicinal use since 2018, many landlords remain unaware of the...

Former President Donald Trump’s recent support for the legalisation of adult-use cannabis in Florida, via Amendment 3, marks a significant shift in both his political strategy and the Republican Party’s approach to drug policy. As Amendment 3 polls above the required 60% threshold for passage...

When the UK’s medical cannabis market was launched in 2018, I remember the palpable sense of optimism. We were confident that this would lead to a rapid and transformative impact on healthcare. However, as we stand in 2024, the journey has proven to be far more challenging than many of us...

Labour’s proposal to ban smoking in pub gardens isn’t just an overreach of government power; it’s a direct threat to personal freedom, common sense, and the pub trade—a vital part of British social life. This proposal should alarm anyone who values evidence-based reform, particularly in the...

Ukraine’s recent legalisation of medical cannabis represents a significant step forward in the nation’s evolving drug policy. However, this progress is marred by a critical omission: the exclusion of post-traumatic stress disorder (PTSD) as a qualifying condition for medical cannabis treatment...

A recent report from the U.S. Centers for Disease Control and Prevention (CDC) has provided compelling evidence that legalising cannabis does not lead to increased use among teenagers. In fact, the data suggests that teen cannabis use has actually declined in states where cannabis has been...

A close friend of mine is a medical cannabis patient. He self-medicates for ADHD and uses around 28 grams per month. Whilst playing a game of Warhammer with him last week (yes, I am a geek), I asked him if he had considered becoming a medical cannabis patient. I assured him I know plenty of good...

The U.S. Drug Enforcement Administration (DEA) has officially announced a public hearing on 2 December 2024 to discuss the proposed rescheduling of cannabis from a Schedule I to a Schedule III substance. This hearing, while significant, delays any final decision until after the November 2024...

Welcome to our monthly breakdown of viewership statistics with MedBud.wiki, taking a deeper look at UK medical cannabis data for July 2024. Each month we delve into the monthly traffic data to highlight trends and enhance understanding of the emerging market. This month saw an impressive 10.3%...